Alnylam Q3 Revenue Rises 17% to $1.46 Billion; Net Income Reaches $2.17 Billion
Alnylam reported Q3 2026 revenue of $1.46 billion, up 17% YoY, and net income of $2.17 billion. Net product revenue rose 52%, driven by AMVUTTRA. Operating income was $345.8 million, down 6%. The company confirmed its 2026 guidance. Key products and studies were highlighted, including AMVUTTRA's growth and clinical trial updates.
How this was made
The 30-second read
Why it matters
Traders can reassess near-term revenue durability from AMVUTTRA-led growth and update expectations for future launch timing and trial progression based on the TRITON-CM enrollment increase and additional clinical readouts (HELIOS-B analyses, brezosiran Phase 1, mivelsiran Phase 2).
Market read
A company-specific earnings print with guidance reiteration plus concrete pipeline and trial-planning updates provides actionable information for positioning in RNAi and rare-disease biotech exposure.
What to watch
Pipeline updates include enrollment target increases and planned pivotal study timing, but the article does not provide updated quantitative guidance ranges or regulatory milestones, leaving some execution risk unpriced.
Background
Alnylam’s Q3 print highlights continued expansion of its TTR franchise (AMVUTTRA) and ongoing ATTR-CM and RNAi pipeline development, alongside a reiterated 2026 financial outlook.
Ticker impact
Alnylam reported Q3 2026 revenue of $1.46B (+17% YoY) and reiterated 2026 guidance, with net product revenue up 52% led by AMVUTTRA.
Likely upward bias as investors price stronger TTR franchise momentum and incremental clinical progress, offset by GAAP operating income and non-GAAP operating income declines.
The article provides concrete quarterly financial prints, franchise growth drivers (AMVUTTRA), and specific pipeline enrollment/plan changes that can affect expectations for future launches and trial timelines.
Market effects
Reinforces demand and clinical momentum in RNAi therapeutics, potentially supporting sentiment toward TTR-focused biotech peers.
No specific regional market shock described beyond international ATTR-CM launch progress (Japan, Germany, Italy).
Moderate global relevance via ATTR-CM and TTR franchise updates that can influence broader rare-disease biotech risk appetite.
Counterpoint
Despite strong revenue and net product growth, operating income (GAAP and non-GAAP) declined, and the large GAAP net income jump is driven by a tax benefit, which may not translate into sustainable earnings power.
Key entities
- companyAlnylam Pharmaceuticals
Reported Q3 2026 revenue and net income, reiterated 2026 guidance, and updated multiple RNAi clinical programs including TRITON-CM enrollment and brezosiran Phase 1 results.
